ONWARD Medical is a global leader in neurotechnology, advancing groundbreaking therapies to help people with spinal cord injuries and other mobility impairments regain movement, function and independence. The funds from this offering will be allocated towards advancing the ARC-IM System, which stabilizes blood pressure of people with spinal cord injuries, and the funds will also be used for expansion of sales of the ARC-EX spinal cord stimulation platform in the U.S., Europe, and other markets.
The company is listed on Euronext Amsterdam, Brussels and Paris, allowing NautaDutilh to advise on matters of both Dutch and Belgian law. The NautaDutilh team acted alongside Skadden and consisted of Paul van der Bijl. Daan Hagelstein, Lentle Nijs and Brian Cuijpers.